Apimeds Clears Merger Hurdle While Nucor Boosts Q2 Outlook: The Niche US Stocks Reshaping Their SectorsGlobal Report·1 day ago, 04:18 AMAPUS+11.33%NUE+0.12%
FDA Approvals and Earnings Beats Propel Specialized US-Listed FirmsGlobal Report·1 day ago, 04:14 AMREPL-11.03%CELC-0.42%
Niche U.S. Equities Face Commercial and Regulatory Tests in Mid-2026Global Report·2 days ago, 04:18 AMAUR+4.37%VSME+6.03%
The Market's Island of Misfit Toys: Separating the Builders from the FakersGlobal Report·2 days ago, 04:13 AMKVUE+1.04%AUR+4.37%
The AI Spillover: How the Market's Edges are Rewiring Real InfrastructureGlobal Report·Jul 24 at 04:13 AMDXST-0.88%BRIA0.00%
The Market's Chaotic Fringe: From AI Pivots to Robotic SurgeryGlobal Report·Jul 22 at 04:17 AMIVF-4.09%STXS+0.78%
9 Health Care Stocks With Whale Alerts In Today’s Sessionbenzinga_article·Jul 9 at 12:35 PMCAPR-64.49%LLY+0.13%
Darden Restaurants To Rally Around 19%? Here Are 10 Top Analyst Forecasts For Tuesdaybenzinga_article·Jun 30 at 08:04 AMBCRX+2.57%EW+0.50%
Replimune Group, Inc. Stock 12‑Month Price Target Raised to $8.17, Implies 30% DownsideTradingView·Jun 29 at 05:20 PMREPL-11.03%
Replimune Group FY 2026: Revenue $0 Net loss $(313.9) M — 10-K SummaryTradingView·Jun 29 at 07:15 AMREPL-11.03%
REPL: FDA accepted RP1 BLA resubmission; cash funds operations into 2027; strong clinical resultsQuartr·Jun 29 at 07:14 AMREPL-11.03%
Replimune FY26 net loss widens to $313.94 million; R&D expenses rise to $221.18 millionPUBT·Jun 29 at 07:03 AMREPL-11.03%
